Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome (Q40371224)

19 September 2017

Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome (English)

1 reference

19 September 2017

1 reference

Hiba M Shendi

1

1 reference

19 September 2017

Deirdre Walsh

series ordinal

2

1 reference

19 September 2017

J David M Edgar

series ordinal

3

1 reference

19 September 2017

language of work or name

1 reference

18 December 2009

1 reference

Rheumatology International

19 September 2017

1 reference

19 September 2017

32

1 reference

19 September 2017

1

1 reference

19 September 2017

249-251

1 reference

https://scigraph.springernature.com/pub.10.1007/s00296-009-1322-8

19 September 2017

0 references

cites work

Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Hyper-IGD syndrome: a new case treated with colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

A patient with hyper-IgD syndrome responding to anti-TNF treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-009-1322-8

Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever

21 January 2018

1 reference

12 December 2020

Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.

1 reference

12 December 2020

Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.

1 reference

12 December 2020

Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency

1 reference

12 December 2020

Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome.

1 reference

12 December 2020

Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group

1 reference

12 December 2020

10.1007/S00296-009-1322-8

Identifiers

DOI

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference